Lantern Pharma Inc
LTRN3.260USD
+0.020+0.62%
收盘 12/19, 16:00（美东）报价延迟15分钟
35.99M总市值
亏损市盈率 TTM
关于 Lantern Pharma Inc 公司
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc简介
公司代码LTRN
公司名称Lantern Pharma Inc
上市日期Jun 11, 2020
CEOSharma (Panna L)
员工数量24
证券类型Ordinary Share
年结日Jun 11
公司地址1920 Mckinney Avenue
城市DALLAS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编75201
电话19722771136
网址https://www.lanternpharma.com/
公司代码LTRN
上市日期Jun 11, 2020
CEOSharma (Panna L)
Lantern Pharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
其他
72.28%
持股股东
持股股东
占比
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
其他
72.28%
股东类型
持股股东
占比
Corporation
13.19%
Venture Capital
9.08%
Investment Advisor
7.80%
Investment Advisor/Hedge Fund
2.08%
Hedge Fund
1.49%
Individual Investor
0.41%
Research Firm
0.09%
其他
65.86%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
75
2.28M
21.15%
-484.54K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bios Equity Partners, LP.
1.08M
9.96%
-157.85K
-12.79%
Jun 30, 2025
Biological Mimetics, Inc
844.13K
7.82%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.84%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Jun 30, 2025
CM Management, LLC
200.00K
1.85%
--
--
Jun 30, 2025
Renaissance Technologies LLC
90.60K
0.84%
+1.80K
+2.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
91.89K
0.85%
+1.39K
+1.53%
Jun 30, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Jun 30, 2025
GWM Advisors LLC
56.51K
0.52%
-3.42K
-5.70%
Jun 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
--
--
Jul 23, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Lantern Pharma Inc的前五大股东是谁？
Lantern Pharma Inc 的前五大股东如下：
Bios Equity Partners, LP.持有股份：1.08M，占总股份比例：9.96%。
Biological Mimetics, Inc持有股份：844.13K，占总股份比例：7.82%。
Prophase Labs Inc持有股份：631.20K，占总股份比例：5.84%。
The Vanguard Group, Inc.持有股份：363.72K，占总股份比例：3.37%。
CM Management, LLC持有股份：200.00K，占总股份比例：1.85%。
Bios Equity Partners, LP.持有股份：1.08M，占总股份比例：9.96%。
Biological Mimetics, Inc持有股份：844.13K，占总股份比例：7.82%。
Prophase Labs Inc持有股份：631.20K，占总股份比例：5.84%。
The Vanguard Group, Inc.持有股份：363.72K，占总股份比例：3.37%。
CM Management, LLC持有股份：200.00K，占总股份比例：1.85%。
Lantern Pharma Inc的前三大股东类型是什么？
Lantern Pharma Inc 的前三大股东类型分别是：
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
Bios Equity Partners, LP.
Biological Mimetics, Inc
Prophase Labs Inc
有多少机构持有Lantern Pharma Inc(LTRN)的股份？
截至2025Q3，共有75家机构持有Lantern Pharma Inc的股份，合计持有的股份价值约为2.28M，占公司总股份的21.15%。与2025Q2相比，机构持股有所增加，增幅为-13.91%。
哪个业务部门对Lantern Pharma Inc的收入贡献最大？
在--，--业务部门对Lantern Pharma Inc的收入贡献最大，创收--，占总收入的--%。
